Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1D | P25100 | 1/20 | 1.00 |
| ▸ | PTAFR | P25105 | 1/20 | 1.00 |
| ▸ | HTR1D | P28221 | 1/20 | 1.00 |
| ▸ | HTR2C | P28335 | 1/20 | 1.00 |
| ▸ | ADRA1B | P35368 | 1/20 | 1.00 |
| ▸ | DRD3 | P35462 | 1/20 | 1.00 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 1/20 | 0.77 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.76 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.76 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.76 |
| ▸ | PRKCG | P05129 | 1/20 | 0.76 |
| ▸ | PRKCB | P05771 | 1/20 | 0.76 |
| ▸ | PRKCA | P17252 | 1/20 | 0.76 |
| ▸ | PRKCH | P24723 | 1/20 | 0.76 |
| ▸ | AKT1 | P31749 | 1/20 | 0.76 |
| ▸ | PRKCI | P41743 | 1/20 | 0.76 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.76 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.76 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30655807 | 1.00 | ADRA1D (1.00) | ADRA1DPTAFRHTR1DHTR2CADRA1B | |
| Platelet Activating Factor SCHEMBL433361 | 1.00 | ADRA1D (1.00) | ADRA1DPTAFRHTR1DHTR2CADRA1B | |
| SCHEMBL30652762 | 1.00 | ADRA1D (1.00) | ADRA1DPTAFRHTR1DHTR2CADRA1B | |
| SCHEMBL30652521 | 1.00 | ADRA1D (1.00) | ADRA1DPTAFRHTR1DHTR2CADRA1B | |
| SCHEMBL34464893 | 1.00 | ADRA1D (1.00) | ADRA1DPTAFRHTR1DHTR2CADRA1B | |
| Platelet Activating Factor SCHEMBL2734461 | 1.00 | ADRA1D (1.00) | ADRA1DPTAFRHTR1DHTR2CADRA1B | |
| SCHEMBL2534238 | 1.00 | ADRA1D (1.00) | ADRA1DPTAFRHTR1DHTR2CADRA1B | |
| SCHEMBL30366852 | 1.00 | ADRA1D (1.00) | ADRA1DPTAFRHTR1DHTR2CADRA1B | |
| SCHEMBL30650457 | 1.00 | ADRA1D (1.00) | ADRA1DPTAFRHTR1DHTR2CADRA1B | |
| Platelet Activating Factor SCHEMBL1392735 | 1.00 | ADRA1D (1.00) | ADRA1DPTAFRHTR1DHTR2CADRA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140287024-A1 | NANOPARTICLE-BASED DELIVERY SYSTEM WITH OXIDIZED PHOSPHOLIPIDS AS TARGETING LIGANDS FOR THE PREVENTION, DIAGNOSIS AND TREATMENT OF ATHEROSCLEROSIS | WANG SHU (US) | 2014-09-25 | — | — | US | claimed |
| US-7973023-B2 | Oxidized lipids and uses thereof in the treatment of inflammatory diseases and disorders | VASCULAR BIOGENICS LTD. (IL) | 2011-07-05 | — | — | US | claimed |
| US-7902176-B2 | Etherified oxidized phospholipids for inducing tolerance to oxidized LDL via mucosal administration; 1-hexadecyl-2-(5'-oxo-pentanyl)-sn-glycero-3-phosphocholine (D-ALLE) | VASCULAR BIOGENICS LTD. (IL) | 2011-03-08 | — | — | US | claimed |
| US-20100048515-A1 | Oxidized lipids and uses thereof in the treatment of inflammatory diseases and disorders | VASCULAR BIOGENICS LTD. (IL) | 2010-02-25 | — | — | US | claimed |
| EP-1626728-A4 | OXIDIZED LIPIDS AND USES THEREOF IN THE TREATMENT OF INFLAMMATORY DISEASES AND DISORDERS | VASCULAR BIOGENICS LTD (IL) | 2009-09-02 | — | — | EP | claimed |
| US-20080261865-A1 | Oxidized Lipids and Uses Thereof in the Treatment of Inflammatory Diseases and Disorders | VASCULAR BIOGENICS LTD. (IL) | 2008-10-23 | — | — | US | claimed |
| US-20070099868-A1 | Oxidized lipids and uses thereof in the treatment of inflammatory diseases and disorders | VASCULAR BIOGENICS LTD. (IL) | 2007-05-03 | — | — | US | claimed |
| EP-1626728-A2 | OXIDIZED LIPIDS AND USES THEREOF IN THE TREATMENT OF INFLAMMATORY DISEASES AND DISORDERS | Vascular Biogenics Ltd. (IL) | 2006-02-22 | — | — | EP | claimed |
| WO-2004106486-A2 | OXIDIZED LIPIDS AND USES THEREOF IN THE TREATMENT OF INFLAMMATORY DISEASES AND DISORDERS | VASCULAR BIOGENICS LTD. (IL) | 2004-12-09 | — | — | WO | claimed |
| US-4879285-A | PLATELET ACTIVATING FACTOR | ROYAL NORTH SHORE HOSPITAL AND AREA HEALTH SERVICE (AU) | 1989-11-07 | — | — | US | claimed |
| US-12569439-B2 | Bottom-up assembly of synthetic extracellular vesicles | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2026-03-10 | — | — | US | disclosed |
| US-20250319190-A1 | APOE LIPOPROTEIN SYSTEMS | KISBEE THERAPEUTICS INC (US) | 2025-10-16 | — | — | US | disclosed |
| CN-117925839-B | Biomarker for evaluating recurrence risk after treatment of multiple myeloma and application thereof | 南通大学附属医院 | 2025-04-01 | — | — | CN | disclosed |
| EP-4522646-A2 | APOE LIPOPROTEIN SYSTEMS | Kisbee Therapeutics, Inc. (US) | 2025-03-19 | — | — | EP | disclosed |
| US-12070463-B2 | Compositions and methods for the treatment of seizure caused by brain tumor | BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE (US) | 2024-08-27 | — | — | US | disclosed |
| US-4804789-A | D-mannite derivatives as starting products for the synthesis of phospholipids | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) | 1989-02-14 | — | — | US | disclosed |
| US-4761404-A | RESPIRATORY SYSTEM DISORDERS, ANTIPYRETICS, ANALGESICS | MERCK & CO., INC. (US) | 1988-08-02 | — | — | US | disclosed |
| US-4734225-A | ANTITUMOR AGENTS | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) | 1988-03-29 | — | — | US | disclosed |
| US-4704462-A | PLATELET-ACTIVATING FACTOR | MERCK & CO., INC. (US) | 1987-11-03 | — | — | US | disclosed |
| EP-0208961-A2 | Phospholipid analogs useful as paf synthesis inhibitors | MERCK & CO. INC. (US) | 1987-01-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250319190-A1 | APOE LIPOPROTEIN SYSTEMS | APOB, APOL1, LDLR | ADRA1D 1631/4885PTAFR 684/4885HTR1D 3764/4885 |
| US-20080261865-A1 | Oxidized Lipids and Uses Thereof in the Treatment of Inflammatory Diseases and Disorders | ALOX15B, GPX4, ALOX12 | ADRA1D 4010/4885PTAFR 1539/4885HTR1D 4829/4885 |
| US-12070463-B2 | Compositions and methods for the treatment of seizure caused by brain tumor | PLG, PLA2G7, PDGFA | ADRA1D 3941/4885PTAFR 10/4885HTR1D 4024/4885 |
| US-20100048515-A1 | Oxidized lipids and uses thereof in the treatment of inflammatory diseases and disorders | ALOX15B, GPX4, ALOX12 | ADRA1D 4010/4885PTAFR 1539/4885HTR1D 4829/4885 |
| US-20070099868-A1 | Oxidized lipids and uses thereof in the treatment of inflammatory diseases and disorders | ALOX15B, GPX4, ALOX12 | ADRA1D 4010/4885PTAFR 1539/4885HTR1D 4829/4885 |
| US-12569439-B2 | Bottom-up assembly of synthetic extracellular vesicles | EXOSC10, PLTP, EXOSC9 | ADRA1D 3085/4885PTAFR 39/4885HTR1D 3779/4885 |
| US-20140287024-A1 | NANOPARTICLE-BASED DELIVERY SYSTEM WITH OXIDIZED PHOSPHOLIPIDS AS TARGETING LIGANDS FOR THE PREVENTION, DIAGNOSIS AND TREATMENT OF ATHEROSCLEROSIS | LDLR, APOB, MSR1 | ADRA1D 1380/4885PTAFR 52/4885HTR1D 4847/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.